Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin Peikert

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Cells|April 30, 2021
Acanthocyte Sedimentation Rate as a Diagnostic Biomarker for Neuroacanthocytosis Syndromes: Experimental Evidence and Physical JustificationAlexis Darras, Kevin Peikert, Antonia Rabe, et al.
Journal of Personalized Medicine|June 2, 2021
Targeting Lyn Kinase in Chorea-Acanthocytosis: A Translational Treatment Approach in a Rare DiseaseKevin Peikert, Hannes Glaß, Enrica Federti, et al.
Parkinsonism & Related Disorders|June 21, 2021
Cardiac manifestation is evident in chorea-acanthocytosis but different from McLeod syndromeSilvio Quick, Felix Matthias Heidrich, Max-Valentin Winkler, et al.
Neurology. Genetics|November 26, 2024
Novel Biallelic Synonymous Exonic Variant in <i>VPS13A</i> Affecting mRNA Splicing: Case ReportRebecca Hui Min Hoe, Yi Zhao, Helen Lisa Ong, et al.
Annals of Clinical and Translational Neurology|October 1, 2025
The Diverse Neuromuscular Spectrum of VPS13A DiseaseAnne Buchberger, Evamaria Riedel, Marie Hackenberg, et al.
Frontiers in Neuroscience|August 2, 2024
Osmotic gradient ektacytometry - a novel diagnostic approach for neuroacanthocytosis syndromesCarolina A Hernández, Kevin Peikert, Min Qiao, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|June 15, 2026
Innate immune signaling as a potential pathomechanistic biomarker for distinct subtypes in amyotrophic lateral sclerosisMarcel Naumann, Stefanie Kretschmer, Johannes Dorst, et al.
Annals of Clinical and Translational Neurology|November 5, 2019
Phenotypes and malignancy risk of different FUS mutations in genetic amyotrophic lateral sclerosisMarcel Naumann, Kevin Peikert, Rene Günther, et al.
Acta Neuropathologica Communications|April 24, 2025
Premature skeletal muscle aging in VPS13A deficiency relates to impaired autophagyVeronica Riccardi, Carlo Fiore Viscomi, Marco Sandri, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|January 28, 2026
RIG-I Mediated Neuron-Specific IFN Type 1 Signaling in FUS-ALS Induces Neurodegeneration and Offers New Biomarker-Driven Individualized Treatment Options for (FUS-)ALSMarcel Naumann, Theresa M Wierschin, Stefanie Kretschmer, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Cells|April 30, 2021
Acanthocyte Sedimentation Rate as a Diagnostic Biomarker for Neuroacanthocytosis Syndromes: Experimental Evidence and Physical JustificationAlexis Darras, Kevin Peikert, Antonia Rabe, et al.
Journal of Personalized Medicine|June 2, 2021
Targeting Lyn Kinase in Chorea-Acanthocytosis: A Translational Treatment Approach in a Rare DiseaseKevin Peikert, Hannes Glaß, Enrica Federti, et al.
Parkinsonism & Related Disorders|June 21, 2021
Cardiac manifestation is evident in chorea-acanthocytosis but different from McLeod syndromeSilvio Quick, Felix Matthias Heidrich, Max-Valentin Winkler, et al.
Neurology. Genetics|November 26, 2024
Novel Biallelic Synonymous Exonic Variant in <i>VPS13A</i> Affecting mRNA Splicing: Case ReportRebecca Hui Min Hoe, Yi Zhao, Helen Lisa Ong, et al.
Annals of Clinical and Translational Neurology|October 1, 2025
The Diverse Neuromuscular Spectrum of VPS13A DiseaseAnne Buchberger, Evamaria Riedel, Marie Hackenberg, et al.
Frontiers in Neuroscience|August 2, 2024
Osmotic gradient ektacytometry - a novel diagnostic approach for neuroacanthocytosis syndromesCarolina A Hernández, Kevin Peikert, Min Qiao, et al.
Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration|June 15, 2026
Innate immune signaling as a potential pathomechanistic biomarker for distinct subtypes in amyotrophic lateral sclerosisMarcel Naumann, Stefanie Kretschmer, Johannes Dorst, et al.
Annals of Clinical and Translational Neurology|November 5, 2019
Phenotypes and malignancy risk of different FUS mutations in genetic amyotrophic lateral sclerosisMarcel Naumann, Kevin Peikert, Rene Günther, et al.
Acta Neuropathologica Communications|April 24, 2025
Premature skeletal muscle aging in VPS13A deficiency relates to impaired autophagyVeronica Riccardi, Carlo Fiore Viscomi, Marco Sandri, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|January 28, 2026
RIG-I Mediated Neuron-Specific IFN Type 1 Signaling in FUS-ALS Induces Neurodegeneration and Offers New Biomarker-Driven Individualized Treatment Options for (FUS-)ALSMarcel Naumann, Theresa M Wierschin, Stefanie Kretschmer, et al.
Pageof 4